Ensign Peak Advisors Inc lowered its position in IQVIA Holdings Inc. (NYSE:IQV – Get Rating) by 17.1% during the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 591,725 shares of the medical research company’s stock after selling 122,421 shares during the period. Ensign Peak Advisors Inc owned 0.31% of IQVIA worth $136,813,000 at the end of the most recent reporting period.
A number of other hedge funds have also recently added to or reduced their stakes in the company. Farallon Capital Management LLC increased its holdings in IQVIA by 6.4% in the first quarter. Farallon Capital Management LLC now owns 3,117,582 shares of the medical research company’s stock worth $720,816,000 after buying an additional 186,826 shares during the last quarter. First Manhattan Co. increased its holdings in IQVIA by 4.7% in the first quarter. First Manhattan Co. now owns 200,778 shares of the medical research company’s stock worth $46,421,000 after buying an additional 9,063 shares during the last quarter. First Republic Investment Management Inc. grew its holdings in IQVIA by 62.3% during the first quarter. First Republic Investment Management Inc. now owns 37,280 shares of the medical research company’s stock valued at $8,620,000 after purchasing an additional 14,314 shares during the last quarter. Guardian Capital LP grew its holdings in IQVIA by 4.4% during the first quarter. Guardian Capital LP now owns 2,695 shares of the medical research company’s stock valued at $623,000 after purchasing an additional 114 shares during the last quarter. Finally, Geneos Wealth Management Inc. grew its holdings in IQVIA by 2.9% during the first quarter. Geneos Wealth Management Inc. now owns 8,889 shares of the medical research company’s stock valued at $2,055,000 after purchasing an additional 253 shares during the last quarter. Institutional investors and hedge funds own 86.77% of the company’s stock.
Wall Street Analysts Forecast Growth
Several equities analysts have commented on IQV shares. Robert W. Baird increased their price target on IQVIA from $260.00 to $265.00 in a report on Friday, July 22nd. Evercore ISI increased their price target on IQVIA from $265.00 to $275.00 in a report on Friday, July 22nd. Credit Suisse Group started coverage on IQVIA in a report on Wednesday, August 24th. They set an “outperform” rating and a $300.00 price target on the stock. Guggenheim increased their price target on IQVIA to $246.00 in a report on Friday, July 22nd. Finally, Barclays lowered their price objective on shares of IQVIA from $255.00 to $235.00 and set an “overweight” rating on the stock in a research note on Monday. Two analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $275.00.
IQVIA Stock Up 1.6 %
IQVIA (NYSE:IQV – Get Rating) last issued its quarterly earnings data on Thursday, July 21st. The medical research company reported $2.44 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.22 by $0.22. IQVIA had a return on equity of 30.21% and a net margin of 8.21%. The company had revenue of $3.54 billion during the quarter, compared to analysts’ expectations of $3.49 billion. During the same period last year, the business earned $1.94 earnings per share. The business’s revenue was up 3.0% on a year-over-year basis. As a group, equities research analysts expect that IQVIA Holdings Inc. will post 9.37 earnings per share for the current fiscal year.
IQVIA Company Profile
IQVIA Holdings Inc provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
- Get a free copy of the StockNews.com research report on IQVIA (IQV)
- Do These Dividend Achievers Deserve A Place In Your Portfolio?
- Darden Restaurants Takes the Low Road Against Inflation
- Why These 3 Stocks Are Off to Hot September Starts
- Inflation Doesn’t Differentiate, But it’s Impact Does
- 3 Downgraded Must-Have Stocks To Put On Your Watchlist
Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter.